Literature DB >> 12425490

Renal failure due to scleroderma with thrombotic microangiopathy developing in a woman treated with carboplatin for ovarian cancer.

M Karim1, E Vaux, D R Davies, P D Mason.   

Abstract

Acute renal failure in association with microangiopathic hemolytic anemia and the pathological finding of thrombotic microangiopathy may occur in a number of conditions including hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, and systemic sclerosis. Distinguishing between these conditions on clinical grounds may be difficult, and further investigations, including serological tests, are normally helpful. We present a patient who was treated with 5 doses of monthly carboplatin chemotherapy for stage IIb ovarian carcinoma and who subsequently developed acute renal failure and microangiopathic hemolysis together with some cutaneous features of systemic sclerosis. Initial serological tests, including anti-nuclear antibody titers measured using rat hepatocytes, were normal, and renal biopsy showed features of microangiopathic hemolysis, fibrinoid change, patchy tubular atrophy, and concentric intimal proliferation. A clinical diagnosis of diarrhea-negative hemolytic uremic syndrome was made and she was treated with plasma exchange and fresh frozen plasma infusion. However, she remained dialysis-dependent. Several weeks later she died following a cardiac arrest. Post-mortem examination revealed medial hypertrophy, concentric intimal proliferation, and thrombi within the small arteries of the kidneys and lungs. Subsequent results from tests taken at the time of her presentation with acute renal failure revealed a normal von Willebrand factor qualitative distribution, and a positive anti-nuclear antibody titer (using a human cell line) in association with positive autoantibodies to RNA polymerase types I, II, and III. Taken together, the clinical, laboratory, and post-mortem findings were suggestive of a diagnosis of systemic sclerosis. We discuss the differential diagnoses, and the associations between these and malignancy and chemotherapy. Finally, we consider the serological tests used for the diagnosis of systemic sclerosis that were, in this case, initially misleading.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12425490     DOI: 10.5414/cnp58384

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  2 in total

Review 1.  Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange.

Authors:  Claudia Rizzo; Sergio Rizzo; Elisabetta Scirè; Danilo Di Bona; Carlo Ingrassia; Giovanni Franco; Roberto Bono; Gerlando Quintini; Calogero Caruso
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

2.  Risk of cancer in patients with scleroderma.

Authors:  J E Pearson; A J Silman
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.